Abstract:Tetrahydropyrido [1,2-a]isoindolone derivatives are potent inhibitors of glycogen synthase kinase 3 beta (GSK3 beta) instead of homologous cyclin-dependent kinase 5 (CDK5). Molecular docking, molecular dynamics simulation, and MM/PBSA energy calculation are utilized to reveal the kinase inhibitors' selective mechanism at the molecular level for improving selectivity. Dynamic cross-correlation map (DCCM) analysis is applied to study the effect of the inhibitor on the interactions between each residue in CDK5 and GSK3 beta. The results of molecular docking indicate that the binding modes of three inhibitors with two kinases are especially similar, and residues in the binding pockets of two kinases are aligned with each other based on the sequence comparing analysis of crystal structures. The analysis of Root Mean Square Deviation (RMSD) with little fluctuation underlies the stability and reliability of systems. Its values of CDK5 (similar to 0.15 nm) are less than GSK3 beta (similar to 0.17 nm), and the inhibitor with higher value holds stronger flexibility and conformational changes of kinases. In terms of energies, the electrostatic and van der Walls energies are the major interactions for differentiating the activity between the same inhibitor and two kinases. And the polar solvation energy plays pivotal role in discriminating the selectivity of kinase inhibitor. The residue decomposition indicates that the residues Glu97 and Thr138 of GSK3 beta are the key residues for differentiating the inhibitor selectivity. On the other hand, in the aspect of inter-residue interaction in one kinase, results indicate that the dynamic correlation of residues is different during the binding process of CDK5 and GSK3 beta with inhibitors. The correlation of Thr138 in the hinge domain of GSK3 beta with that of residues Val135-Gln206 is positive, while the correlation of Gln85 and Cys83 similar to Ala150 in CDK5 is unclear, which is a key factor to distinguish inhibitor selectivity.

3D QSAR for GSK-3β Inhibition by Indirubin Analogues

Pinpointing top inhibitors for GSK3β from pool of indirubin derivatives using rigorous computational workflow and their validation using molecular dynamics (MD) simulations

Synthesis and biological evaluation of novel 4-azaindolyl-indolyl-maleimides as glycogen synthase kinase-3β (GSK-3β) inhibitors

Structure-based Rational Quest for Potential Novel Inhibitors of Human HMG-CoA Reductase by Combining CoMFA 3D QSAR Modeling and Virtual Screening.

In silico design novel (5-imidazol-2-yl-4-phenylpyrimidin-2-yl)[2-(2-pyridylamino)ethyl]amine derivatives as inhibitors for glycogen synthase kinase 3 based on 3D-QSAR, molecular docking and molecular dynamics simulation

Synthesis and biological evaluation of novel 4-azaindolyl-indolyl-maleimides as glycogen synthase kinase-3beta (GSK-3beta) inhibitors.

Molecular models of cyclin-dependent kinase 4 complexed with indirubin and its analogues

Design, Synthesis and Evaluation of 7-Azaindazolyl-indolyl-maleimides As Glycogen Synthase Kinase-3Β (Gsk-3Β) Inhibitors

Study of the Inhibition of Cyclin-Dependent Kinases with Roscovitine and Indirubin-3′-oxime from Molecular Dynamics Simulations

Exploring the Selectivity of Tetrahydropyrido[1,2-a]isoindolone Derivatives to GSK3 beta and CDK5 by Computational Methods

3D-QSAR Study on 2,3-Dihydroimidazo[4,5]-pyridin-2-one Derivatives with a Meta Substitution Pattern As V600E BRAF Inhibitors

3D Qsar Studies on Gsk-3 Inhibition by Aloisines

Indirubin-3-Oxime Effectively Prevents 6OHDA-Induced Neurotoxicity in PC12 Cells via Activating MEF2D Through the Inhibition of GSK3β

Identification, Structure Modification, and Characterization of Potential Small-Molecule SGK3 Inhibitors with Novel Scaffolds

Understanding the Selectivity of Inhibitors Toward PI4KIIIα and PI4KIIIβ Based Molecular Modeling

Substituted indolin-2-ones as p90 ribosomal S6 protein kinase 2 (RSK2) inhibitors: Molecular docking simulation and structure-activity relationship analysis.

Integrated computational approaches for identification of potent pyrazole-based glycogen synthase kinase-3β (GSK-3β) inhibitors: 3D-QSAR, virtual screening, docking, MM/GBSA, EC, MD simulation studies

Computational Insights into Novel Inhibitor N-(3-(tert-Butylcarbamoyl)-4-methoxyphenyl)-indole and Ingliforib Specific against GP Isoenzyme Dimers Interaction Mechanism

Discovery of New GSK-3β Inhibitors Through Structure-Based Virtual Screening

3D-QSAR and Docking Study on 3-Benzimidazol-2-ylhydroquinolin-2-one Derivatives As VEGFR-2 Tyrosine Kinase Inhibitors

Pharmacological properties of indirubin and its derivatives